NCT02710734 2024-12-24
Risk Enabled Therapy After Initiating Neoadjuvant Chemotherapy for Bladder Cancer (RETAIN)
Fox Chase Cancer Center
Phase 2 Active not recruiting
Clinical Trials
3 trialsNCT02246738 2020-12-10
Initial Evaluation of a Telomerase-based Circulating Tumor Cell Assay in Bladder Cancer Cohorts
Abramson Cancer Center at Penn Medicine
Completed
NCT01520038 2019-11-26
Adjuvant Proton Therapy or IMRT for the Treatment of Bladder Cancer
Abramson Cancer Center at Penn Medicine
Phase 1/2 Completed